OS Therapies Incorporated — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
OS Therapies is a clinical-stage biotechnology company developing treatments for osteosarcoma and other solid tumors. Its lead candidate is OST-HER2, with an additional OST-tADC platform. The company reported unaudited results for the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
One osteosarcoma clinical trial was ongoing at March 31, 2024. The company had no product revenue and remains pre-commercial.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $361,809 | $753,784 |
| General and administrative expense | $268,423 | $294,247 |
| Loss from operations | $(630,232) | $(1,048,031) |
| Interest expense | $(828,760) | $(798,938) |
| Net loss | $(1,458,992) | $(1,846,969) |
| Net loss available to common shareholders | $(1,490,242) | $(1,878,219) |
| Basic and diluted loss per share | $(0.13) | $(0.18) |
| Net cash used in operating activities | $(641,729) | $(428,186) |
| Net cash provided by financing activities | $702,978 | $610,775 |
Cash was $100,231 at March 31, 2024, compared with $38,982 at December 31, 2023. Total assets were $1.05 million, while total liabilities were $26.56 million. Stockholders’ deficit was $25.51 million, compared with $24.02 million at year-end 2023.
Current liabilities included $2.80 million of accounts payable, $2.28 million of accrued convertible-note interest, a $5.06 million redemption premium, a $100,000 short-term demand loan, and convertible notes with aggregate carrying amounts of approximately $15.5 million. The notes generally mature on October 31, 2024 unless converted earlier.
Deferred offering costs increased to $941,338 from $751,050 at December 31, 2023. No meaningful margin analysis is applicable because the company had no revenue.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined approximately 52%, primarily because of lower vendor costs associated with the Phase IIb clinical trial and the OST-tADC platform.
- General and administrative expense decreased approximately 9%.
- Operating loss improved by approximately $418,000, and net loss improved by approximately $388,000.
- Interest expense increased approximately $30,000, reflecting continuing accretion of debt discounts and interest on convertible notes.
- Operating cash use increased approximately $214,000, despite the lower reported net loss, while financing proceeds increased approximately $92,000.
- Preferred Stock A was converted into 1,302,082 shares of common stock on February 9, 2024. Common shares outstanding increased to 11,982,082 from 10,680,000 at December 31, 2023, and no preferred shares remained outstanding.
- Accumulated deficit increased to $31.01 million from $29.52 million at year-end 2023.
Guidance, Outlook, Risks, and Unusual Items
- Management expects research and development and general and administrative expenses, and operating losses, to increase as product candidates advance and public-company costs grow.
- The company states that its existing cash and private-placement proceeds are expected to fund operations for approximately three to six months. Management is seeking additional equity capital, but provides no assurance that financing will be successful.
- The financial statements are prepared on a going-concern basis, but recurring losses, negative operating cash flow, minimal cash, and substantial liabilities raise substantial doubt about the company’s ability to continue as a going concern.
- The registration statement for the anticipated initial public offering became effective on February 14, 2024, but no securities had been sold under it as of the filing. The company continued to capitalize offering costs.
- Through April 22, 2024, the company issued an additional $750,000 of Group F convertible notes. The notes bear 6% interest and mature October 31, 2024.
- Convertible notes generally convert in a future qualified financing or anticipated initial public offering, often at a discount to the offering price. Bridge notes convert at 50% of the next financing price, subject to a $50 million valuation ceiling, creating significant potential dilution.
- On April 12, 2024, Noble Capital Markets commenced arbitration alleging that the company owed 474,134 additional common shares under an anti-dilution provision. The company disputes the claim but reserved the shares pending resolution.
- As of March 31, 2024, $644,287 was due to George Clinical under the clinical research services agreement. The total agreement budget is approximately $2.44 million.
- Potential future milestone obligations include up to $5.0 million to Advaxis upon specified regulatory or clinical events and up to $22.375 million to BlinkBio for specified development and regulatory milestones, in addition to potential royalties.
- Management concluded that disclosure controls and procedures were not effective as of March 31, 2024 because of insufficient segregation of duties and inadequate written policies and procedures, attributable to limited personnel.
Most Important Facts for Investors to Verify
- Whether the company can obtain sufficient equity or other financing before its cash resources are exhausted.
- Whether convertible notes, accrued interest, redemption premiums, and bridge-note inducement shares will convert, be repaid, or generate substantial dilution.
- The status and outcome of the Noble Capital arbitration and the potential issuance of 474,134 shares.
- Clinical progress, enrollment, costs, and future milestones for OST-HER2 and the OST-tADC platform.
- Whether the anticipated initial public offering proceeds, timing, and terms are sufficient to address the going-concern uncertainty.
- Whether management improves disclosure controls and internal control over financial reporting.